Last $129.63 USD
Change Today -0.71 / -0.54%
Volume 770.0K
EW On Other Exchanges
New York
As of 8:04 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - $137.19
52 Week Low
02/3/14 - $63.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

edwards lifesciences corp (EW) Related Businessweek News

No Related Businessweek News Found

edwards lifesciences corp (EW) Details

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers surgical heart valve therapy products, such as tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve; and produces pericardial valves from biologically inert animal tissue. Its surgical heart valve therapy products include Carpentier-Edwards PERIMOUNT pericardial valve that comprise PERIMOUNT Magna Ease valves for aortic and mitral replacement; ThruPort systems that enable minimal incision valve surgery; and protection cannulae that is used during cardiac surgery in venous drainage, aortic perfusion, venting, and cardioplegia delivery. The company also provides transcatheter heart valves portfolio that includes technologies designed to treat heart valve disease using catheter-based approaches, as well as critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; Swan-Ganz line of pulmonary artery and PreSep continuous venous oximetry catheters for measuring central venous oxygen saturation; VolumeView sensor-catheters; FloTrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology for fluid optimization; and EV1000 clinical monitoring platform, which displays a patient's physiologic status. Its critical care products also include disposable pressure monitoring devices and closed blood sampling systems to help protect patients and clinicians from the risk of infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as balloon-tipped, catheter-based embolectomy products, surgical clips, and clamps. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

8,600 Employees
Last Reported Date: 02/28/14
Founded in 1999

edwards lifesciences corp (EW) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $879.8K
Corporate Vice President of Europe, Middle Ea...
Total Annual Compensation: $607.8K
Corporate Vice President of Heart Valve Thera...
Total Annual Compensation: $440.6K
Compensation as of Fiscal Year 2013.

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corp.(NYSE:EW) dropped from S&P 500 Value Index

Edwards Lifesciences Corp.(NYSE:EW) dropped from S&P 500 Value Index

Edwards Lifesciences Provides Gross Profit Margin Guidance for the Fourth Quarter of 2014 and Sales Guidance for the Year 2015; Revises Earnings Guidance for the Year 2014

Edwards Lifesciences provided gross profit margin guidance for the fourth quarter of 2014 and sales guidance for the year 2015 and revised earnings guidance for the year 2014. The company expects gross profit margin to grow to 75%, up from 74% in the fourth quarter and for the full year of 2014. The original guidance for gross margin for the full year was 73%. For the year 2014, the company expects free cash flow of $375 million to $425 million. The company expects that total sales will exceed the top end of the company's original range of $2.25 billion. Adjusted diluting -- diluted earnings per share, the company expects in the range of $3.90 to $4.10, representing high teens EPS growth over current $3.33 to $3.39 guidance for EPS in 2014. The company has tax assumptions of 21% to 23% effective tax rate. This assumes the renewal of the R&D tax credit and the company's diluted shares outstanding assumption is 109 million to 111 million shares. The company expects organic sales growth of approximately $200 million and that's how the company get to the midpoint of that $2.3 billion to $2.5 billion range of expected revenues. The company announced that its 2015 guidance is sales of $2.3 billion to $2.5 billion. This reflects pretty significant headwinds from strengthening of the U.S. currency relative to the foreign currencies where the company do business. Overall for 2015, the see underlying sales growth at about 15% to 20%.

Edwards Lifesciences Corporation Appoints Nicholas J. Valeriani to its Board

Edwards Lifesciences Corporation announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $129.63 USD -0.71

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $178.20 USD -0.39
Endo International PLC $78.87 USD -1.15
Hologic Inc $29.35 USD -0.165
Intuitive Surgical Inc $517.57 USD -7.81
Mettler-Toledo International Inc $303.05 USD -1.72
View Industry Companies

Industry Analysis


Industry Average

Valuation EW Industry Range
Price/Earnings 18.1x
Price/Sales 6.2x
Price/Book 6.8x
Price/Cash Flow 17.8x
TEV/Sales 5.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at